Welcome to the Cytokine-Based Cancer Immunotherapies Summit
The renewed interest in the anti-tumour properties of cytokines has led to an increase in the number of clinical trials that explore the safety and efficacy of cytokine-based drugs, not only as single agents, but also in combination with other immunomodulatory drugs.
Soluble factors within the tumor microenvironment (TME) orchestrating a variety of wide-ranging biologic effects and interventions in this field can help stimulate immunotherapeutic responsiveness. The virtual Cytokine-Based Cancer Immunotherapies Summit has been set up to give drug developers insight into the latest clinical results and stimulate discussions around how to take immuno-oncology combinations forward.
This is your opportunity to join your peers from industry and academia to discuss key topics including:
Determining the underlying mechanisms of T-cell exclusion from the tumor in order to turn cold tumors ‘hot’ with Roche, Novartis and Werewolf Therapeutics
Optimize cytokine engineering to ensure stability and improve the favorable risk benefit profile with Synthekine, Alkermes and John Hopkinsh
Overcome toxicity challenges by ensuring tumor targeting is selective and therefore enhances the anti-tumor response with SQZ Biotechnologies, IGM Biosciences, CytomX and Philogen
Take a deep dive into preclinical cancer models covering both in-vitro and in-vivo studies and how these are unveiling the most favoured pharmaceuticals properties of therapeutic cytokines with John Hopkins and University of Western Australia
Uncover the latest data coming out of the clinic of cytokines in combination with checkpoint inhibitors and monoclonal anitbodies with National Cancer Institute